Bay City Capital is a life sciences venture capital firm that invests in opportunities across the various life sciences sectors in companies at all stages of development. Established in 1997, the firm has managed eight venture capital funds representing over $1.6 billion in capital commitments. Bay City Capital has invested in over 100 life sciences companies globally, including Civitas, Dermira, Epizyme, Epocrates, Hyperion Therapeutics, Idev Technologies, Ion Torrent Systems, MAP Pharmaceuticals, Medarex, Nabsys, NextWave Pharmaceuticals, Oculex Pharmaceuticals, Pharmion, Reliant Pharmaceuticals, and Sunesis Pharmaceuticals.
Looking for a particular Bay City Capital employee's phone or email?
The Bay City Capital annual revenue was $24 million in 2026.
Judy Koh is the CFO of Bay City Capital.
15 people are employed at Bay City Capital.
Bay City Capital is based in San Francisco, California.
The NAICS codes for Bay City Capital are [5239, 523, 52].
The SIC codes for Bay City Capital are [67, 679].